-
.
- Ελληνικά
The Health Insurance Agency informs beneficiaries that, despite multiple efforts, it has not been possible to secure antidiabetic medicines of the GLP-1 Analogue class.
It is noted that, in addition to the drug with active substance Liraglutide and trade name VICTOZA (which was until recently reimbursed by the SHI), the Agency took steps to secure another GLP-1 Analogue with active substance Lixisenatide or Exenatide or Dulaglutide. However, it was not possible to secure any drug falling into the same category.
The inability to supply is due to problems in the production chain at the international level, due to increased global demand, which exceeds the quantities produced, affecting both the Cypriot market and many other countries.
Beneficiaries are requested to contact their treating physician directly regarding the appropriate treatment.
(EAT/EP)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source
